Pill with g 12
Pro Research Analysisby 
Searched over 200M research papers
Understanding the Pill with G 12: BG-12 and Its Efficacy in Multiple Sclerosis Treatment
Introduction to BG-12 (Dimethyl Fumarate)
BG-12, also known as dimethyl fumarate, is an oral medication developed for the treatment of relapsing-remitting multiple sclerosis (RRMS). This condition is typically managed with injectable treatments like interferon or glatiramer acetate. BG-12 offers a promising oral alternative, potentially improving patient adherence and convenience.
Efficacy of BG-12 in Relapsing-Remitting Multiple Sclerosis
Annualized Relapse Rate Reduction
A phase 3, placebo-controlled study evaluated the efficacy of BG-12 in patients with RRMS. The study compared two dosing regimens of BG-12 (240 mg twice daily and three times daily) against a placebo and glatiramer acetate as a reference comparator. Results showed that both BG-12 dosing regimens significantly reduced the annualized relapse rate compared to placebo. Specifically, the twice-daily regimen reduced the relapse rate by 44%, and the thrice-daily regimen by 51%, while glatiramer acetate achieved a 29% reduction.
Impact on Disability Progression and Lesions
Although reductions in disability progression were not statistically significant, BG-12 demonstrated a notable impact on neuroradiologic outcomes. Both dosing regimens of BG-12 significantly reduced the number of new or enlarging T2-weighted hyperintense lesions and new T1-weighted hypointense lesions compared to placebo. These findings suggest that BG-12 not only helps in reducing relapse rates but also in controlling the progression of brain lesions associated with multiple sclerosis.
Safety and Adverse Events
The safety profile of BG-12 was also assessed in the study. Common adverse events associated with BG-12 included flushing and gastrointestinal issues. Importantly, no malignant neoplasms or opportunistic infections were reported, and while lymphocyte counts decreased, this did not lead to significant clinical concerns.
Conclusion
BG-12 (dimethyl fumarate) has shown significant efficacy in reducing relapse rates and improving neuroradiologic outcomes in patients with relapsing-remitting multiple sclerosis. Its oral administration offers a convenient alternative to injectable treatments, potentially enhancing patient adherence. The safety profile is acceptable, with manageable adverse events. These findings position BG-12 as a valuable option in the therapeutic arsenal against multiple sclerosis.
Sources and full results
Most relevant research papers on this topic